P161

Metabolic effects of switching to tenofovir alafenamide/emtricitabine/ bictegravir (B/F/TAF) from tenofovir difumarate (TDF) or tenofovir alafenamide (TAF) sparing regimens. (METABIC Study)

C. Busca[1,2], D. Ortega[1,2], L Martin-Carbonero[1,2], R Mican[1,2], L Ramos[1,2], ME Valencia[1,2], R Montejano[1,2], M Montes[1,2], M Diaz-Almiron[3], A. Delgado[1], and Jose I Bernardino[1,2].

(1) HIV Unit Internal Medicine Department. Hospital La Paz. IdiPAZ. Madrid. (2) Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC), Madrid (3) Biostatistic Unit. La Paz Research Institute. IdiPAZ. Madrid.

Background and aim

- Cardiovascular disease is the leading cause of death in the general population and a frequent comorbidity in people with HIV (PWH), in fact PWH have a 2-fold higher risk for cardiovascular disease than negative controls.
- Most of the published studies switching from TDF-based regimens to TAF-based regimens raise concern about a worse metabolic profile (weight gain, higher lipids, and liver steatosis) in PWH. Few studies have explored the metabolic impact of B/F/TAF when switching from a previous regimen without TDF or TAF.
- We aim to assess changes in lipid fractions, glucose, and triglyceride to glucose ratio (TyG) after switching from a TDF/TAF sparing regimen to B/F/TAF at 6 and 12 months.

Patients and Methods

- A retrospective observational study of PWH who switched to B/F/TAF from ART regimens without TDF or TAF.
- We included participants who started B/F/TAF from January 2019 to May 2022, with at least six months of follow-up, and at least two blood samples in the period.
- The primary endpoint was the absolute change in lipid fractions at six months.
- Secondary outcomes were changes in lipid fractions at 12 months and other metabolic parameters (glucose, creatinine, and the serum marker for hepatic steatosis triglycerides to glucose ratio (TyG) with a cut-off (> 8.36) at 6 and 12 months.
- Mixed Linear Regression models with random intercept and time as a fixed effect were used to analyse these changes.

Table 1: Changes in metabolic and renal parameters *

Parameter	Baseline N= 147	6 months N= 146	12 months N=137
Total Cholesterol mg/dl			
Mean (95% CI)	182.8 (176.3,189.2)	173.3 (166.8, 179.8)	175.2 (168.6-181.8)
Change from baseline, (95% CI); p-value		-9.45 (-16.43, -2.48); p=0.004	-7.54 (-14.67, -0.41); p=0.034
LDL cholesterol mg/dl			
Mean (95% CI)	107.02 (101.3, 112.7)	100.62 (94.9, 106.28)	105.01 (99.23, 110.78)
Change from baseline, (95% CI); p-value		-6.39 (-12.9, 0.12); p=0.056	-2.01 (-8.67, 4.65); p=1.0
HDL cholesterol mg/dl			
Mean (95% CI)	46.46 (44.48, 48,44)	45.60 (43.62, 47.58)	43.91 (41.90, 45.92)
Change from baseline, (95% CI); p-value		-0.855 (-2.65, 0.94); p=0.761	-2.55 (-4.39, -0.70); p =0.003
Triglycerides mg/dl			
Mean (95% CI)	155.74 (138.95, 172.53)	135.89 (119.10, 152.68)	144.75 (127.51, 161.99)
Change from baseline, (95% CI); p-value		-19.85 (-41.92, 2.22); p=0.093	-10.98 (-33.58, 11.60); p=0.727
TC: HDL ratio			
Mean (95% CI)	4.12 (3.93, 4.30)	3.89 (3.71, 4.08)	4.14 (3.95, 4.33)
Change from baseline, (95% CI); p-value		-0.22 (-0.44, -0.001);p=0.048	0.02 (-0.20, 0.24); p=1.0
Glucose mg/dl			
Mean (95% CI)	99.23 (94.80, 103.67)	101.56 (97.13, 105.99)	102.86 (98.37, 107.34)
Change from baseline, (95% CI); p-value		2.32 (-6.37, 1.72); p=0.50	3.62 (-7.76, 0.52); p =0.1088
Creatinine mg/dl			
Mean (95% CI)	0.93 (0.89, 0.96)	0.96 (0.92, 0.99)	0.96 (0.93, 1.0)
Change from baseline, (95% CI); p-value		0.03 (0.009, 0.05); p=0.0025	0.03 (0.013, 0.06); p< 0.001
CKD-EPI mg/min			
Mean (95% CI)	85.71 (83.60, 87.82)	83.84 (81.73, 85.95)	82.97 (80.84, 85.10)
Change from baseline, (95% CI); p-value		-1.87 (-3.62, -0.11); p=0.0319	-2.73 (-4.52, -0.95); p< 0.001
TyG ratio			
Mean (95% CI)	8.79 (8.69, 8.89)	8.64 (8.55, 8.74)	8.74 (8.64, 8.84)
Change from baseline, (95% CI); p-value		-0.147 (-0.25, -0.04); p=0.0023	-0.005 (-0.158, 0.005); p=0.7387

Multiple comparisons adjusted using the Bonferroni Method













Results

- A total of 147 PWH were included: median (P25-75) age 55 years (46-58), 81% male, 89% Caucasian, CD4+ T cell count 675 cells/mm^3 (449-879), 79.6% HIV-RNA < 50 cp/ml.
- 44 (30%) had hypertension, 72 (49%) dyslipidemia, 24 (16%) diabetes, and 46% had obesity or overweight.
- Most of the participants (97; 66%) switched from integrase inhibitor-based triple therapy (ABC/3TC + dolutegravir or raltegravir), and 28 (19%) received a boosted protease inhibitor (9 patients 3TC +PI, 10 patients PI monotherapy).
- At 6 and 12 months there was a significant reduction in total cholesterol of -9.45 mg/dl (95% CI -16.43, -2.48; p=0.004) and -7.54 mg/dl (95% CI -14.67, -0.41; p=0.034).
- At 6 months there was a significant reduction in the TyG ratio (for hepatic steatosis) of -0.147 (95% CI -0.25, -0.04; p=0.0023). The percentage of patients with TyG > 8.38 at baseline, 6 and 12 months was 75.2, 65.1, and 71.7. These differences were not statistically significant.
- At 6 and 12 months there was a significant reduction in glomerular filtration rate (CPK-EPI): -1.87 ml/min (95% IC -3.62, -0.11; p=0.0319) and -2.73ml/min (-4.52, -0.95; p < 0.001) respectively.

Conclusion

In our real-life cohort, the effect of switching ART regimens without TDF/TAF to triple therapy with B/F/TAF improved total cholesterol at both 6 and 12 months and was neutral for the rest of the metabolic parameters after one year of follow-up.